07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

Zorvolex lower dose submicron diclofenac regulatory update

FDA approved an sNDA from Iroko for Zorvolex to treat osteoarthritis pain in adults. The product is approved in the U.S. to treat mild to moderate acute pain in adults. Iroko launched Zorvolex in January....
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Iroko, Calox de Costa Rica deal

Iroko’s Iroko Pharmaceuticals Inc. affiliate granted Calox exclusive rights in Colombia, Costa Rica, Dominican Republic, El Salvador, Guatemala, Nicaragua, Honduras, Panama and Venezuela to develop and commercialize pain product Zorvolex submicron diclofenac. Calox will be...